PEP-010 has received orphan drug designation for pancreatic cancer, emphasizing the need for novel treatments in this high-mortality disease. The peptide disrupts Caspase-9 and PP2A interaction, ...
French biotech Pep-Therapy SAS is in the midst of raising a €20 million (US$21.62 million) round and, at the same time, prospecting for potential partners after winning FDA orphan drug designation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results